PureTech Health Plc (PRTC)

Go back to PureTech Health Plc (PRTC)

PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting

April 12, 2021 7:00 AM UTC

Novel antibody demonstrates highly specific and highly potent targeting of immunosuppressive 1 T cells from cancer patients

Enriched in many intractable solid tumors and blood of cancer patients, 1 T cells represent important new target for cancer immunotherapy

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to... More